[{"address1": "#3 Bethesda Metro Center", "address2": "Suite 700", "city": "Bethesda", "state": "MD", "zip": "20814", "country": "United States", "phone": "877 424 2429", "website": "https://www.cnbxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gabriel  Yariv", "age": 47, "title": "President, COO & Executive Chairman", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 241667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Uri  Ben-Or CPA, CPA, M.B.A., MBA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 40321, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eyal  Barad", "age": 58, "title": "Co-Founder, CEO & Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 269149, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sanja  Goldberg", "age": 47, "title": "Chief Technology Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 48120, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Noam  Permont", "title": "Vice President of Public Relations & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sigalit  Ariely-Portnoy Ph.D.", "age": 59, "title": "Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tal  Mofkadi Ph.D.", "title": "Financial Advisor & Member of Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yasha  Borstein", "age": 60, "title": "Chief Data Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yaakov  Waksman", "age": 71, "title": "Head of Cannabidiol Research", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ilya  Reznik M.D.", "title": "Head of Neuropsychiatry Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.01336, "open": 0.013, "dayLow": 0.013, "dayHigh": 0.013, "regularMarketPreviousClose": 0.01336, "regularMarketOpen": 0.013, "regularMarketDayLow": 0.013, "regularMarketDayHigh": 0.013, "beta": 0.823, "volume": 1037, "regularMarketVolume": 1037, "averageVolume": 271862, "averageVolume10days": 121510, "averageDailyVolume10Day": 121510, "marketCap": 404448, "fiftyTwoWeekLow": 0.01, "fiftyTwoWeekHigh": 0.1, "priceToSalesTrailing12Months": 0.8095404, "fiftyDayAverage": 0.0132, "twoHundredDayAverage": 0.01555, "currency": "USD", "enterpriseValue": 1636920, "floatShares": 27067187, "sharesOutstanding": 31111400, "heldPercentInstitutions": 0.106709994, "impliedSharesOutstanding": 31111400, "bookValue": -0.074, "lastFiscalYearEnd": 1693440000, "nextFiscalYearEnd": 1725062400, "mostRecentQuarter": 1701302400, "netIncomeToCommon": -3531088, "trailingEps": -0.09, "lastSplitFactor": "1:120", "lastSplitDate": 1652313600, "enterpriseToRevenue": 3.276, "enterpriseToEbitda": -2.737, "52WeekChange": -0.75, "SandP52WeekChange": 0.3288405, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CNBX", "underlyingSymbol": "CNBX", "shortName": "CNBX PHARMACEUTICALS INC", "longName": "CNBX Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1188912600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "49b2f3d8-1ffd-3bd2-b80f-1c6776064f6d", "messageBoardId": "finmb_130738072", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.013, "recommendationKey": "none", "totalCash": 81647, "totalCashPerShare": 0.003, "ebitda": -598153, "totalDebt": 1314120, "quickRatio": 0.033, "currentRatio": 0.061, "totalRevenue": 499602, "revenuePerShare": 0.032, "returnOnAssets": -0.94854, "freeCashflow": 180682, "operatingCashflow": -88452, "grossMargins": 1.0, "ebitdaMargins": -1.19726, "operatingMargins": -1.92202, "financialCurrency": "USD", "trailingPegRatio": null}]